Your browser doesn't support javascript.
loading
Liquid biopsy in triple-negative breast cancer: unlocking the potential of precision oncology.
Mazzeo, R; Sears, J; Palmero, L; Bolzonello, S; Davis, A A; Gerratana, L; Puglisi, F.
Afiliación
  • Mazzeo R; Department of Medical Oncology, CRO Aviano, National Cancer Institute, IRCCS, Aviano; Department of Medicine, University of Udine, Udine, Italy.
  • Sears J; Department of Medicine, Washington University in St. Louis, St. Louis.
  • Palmero L; Department of Medical Oncology, CRO Aviano, National Cancer Institute, IRCCS, Aviano; Department of Medicine, University of Udine, Udine, Italy.
  • Bolzonello S; Department of Medical Oncology, CRO Aviano, National Cancer Institute, IRCCS, Aviano.
  • Davis AA; Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, USA.
  • Gerratana L; Department of Medical Oncology, CRO Aviano, National Cancer Institute, IRCCS, Aviano; Department of Medicine, University of Udine, Udine, Italy. Electronic address: lorenzo.gerratana@outlook.com.
  • Puglisi F; Department of Medical Oncology, CRO Aviano, National Cancer Institute, IRCCS, Aviano; Department of Medicine, University of Udine, Udine, Italy.
ESMO Open ; 9(10): 103700, 2024 Oct.
Article en En | MEDLINE | ID: mdl-39288656
ABSTRACT
In the era of precision oncology, the management of triple-negative breast cancer (TNBC) is rapidly changing and becoming more complicated with a variety of chemotherapy, immunotherapy, and targeted treatment options. Currently, TNBC treatment is based on prognostic and predictive factors including immunohistochemical biomarkers [e.g. programmed death-ligand 1 (PD-L1)] and germline BRCA mutations. Given the current limitation of existing biomarkers, liquid biopsies may serve as clinically useful tools to determine treatment efficacy and response in both the (neo)adjuvant and metastatic settings, for detecting early relapse, and for monitoring clonal evolution during treatment. In this review, we comprehensively summarize current and future liquid biopsy applications. Specifically, we highlight the role of circulating tumor cell characterization, circulating tumor DNA, and other preclinical liquid biopsy technologies including circulating exosomes, RNA liquid biopsy, and circulating immune-based biomarkers. In the near future, these biomarkers may serve to identify early disease relapse, therapeutic targets, and disease clonality for patients with TNBC in the clinical setting.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Biomarcadores de Tumor / Medicina de Precisión / Neoplasias de la Mama Triple Negativas Límite: Female / Humans Idioma: En Revista: ESMO Open Año: 2024 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Biomarcadores de Tumor / Medicina de Precisión / Neoplasias de la Mama Triple Negativas Límite: Female / Humans Idioma: En Revista: ESMO Open Año: 2024 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido